“Janssen did not conduct genetic toxicology studies as they are not appropriate for antibody therapies.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗
Carcinogenicity
Not conducted (advanced cancer, ICH S9)
“In addition, Janssen did not conduct dedicated studies to assess fertility or carcinogenicity as these studies are not necessary to support the development of a drug intended to treat patients with advanced cancer.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗
Reproductive & developmental
Not conducted; weight-of-evidence (EGFR/MET knockouts, lazertinib rat EFD, zalutumumab monkey EFD); embryofetal warning
“Rather than conducting a dedicated embryofetal development study, Janssen provided a weight-of-evidence-based assessment of the potential for amivantamab to cause reproductive and embryofetal toxicity.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗
Safety pharmacology
Incorporated into 1-month, 6-week and 3-month monkey studies (CV, respiratory, observational CNS)
“Separate safety pharmacology studies were not conducted with amivantamab; however, the 1-month non-Good Laboratory Practice (GLP) tolerability study, and the 6-week and the 3-month toxicity GLP studies in cynomolgus monkeys incorporated cardiovascular and respiratory assessments as well as observational central nervous system (CNS) assessments (body temperature and clinical signs).”
✓ VerifiedFDA multi-discipline review, p. 55Source ↗